A Randomised, Open-labelled, 4-period Crossover Trial Characterising Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 Administered Once, Twice or Thrice Daily and Biphasic Human Insulin 30 Administered Once Daily in Subjects With Type 2 Diabetes.

Trial Profile

A Randomised, Open-labelled, 4-period Crossover Trial Characterising Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 Administered Once, Twice or Thrice Daily and Biphasic Human Insulin 30 Administered Once Daily in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2017

At a glance

  • Drugs Insulin aspart/insulin protamine aspart; Insulin suspension isophane/insulin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Aug 2009 Results were published in Diabetes Care.
    • 23 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top